Acumen Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on its lead product candidate, sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 monoclonal antibody that selectively targets toxic soluble amyloid-beta oligomers (AβOs); sabirnetug has completed the phase 1 INTERCEPT-AD trial and is advancing in the phase 2 ALTITUDE-AD trial in early symptomatic Alzheimer's patients, as well as an open-label extension study; it also pursues a subcutaneous formulation of sabirnetug via collaboration with Halozyme Therapeutics, Inc. using ENHANZE drug delivery technology, and explores enhanced brain delivery therapies combining AβO-selective antibodies with JCR Pharmaceuticals' J-Brain Cargo blood-brain barrier-penetrating platform under a 2025 strategic collaboration, option, and license agreement. Founded in 1996 and headquartered in Newton, Massachusetts, Acumen operates primarily in the United States with a pipeline centered on novel immunotherapy approaches for neurodegeneration.
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer's Disease
Acumen's Late-2026 Sabirnetug Readout Is A Viable Bet
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Acumen Pharmaceuticals Q1 Earnings Call Highlights
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Analysts Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Target Price at $7.00
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio